Correction | GenomeWeb

Correction

Premium

An RNAi News report on Nov. 14 described the Aventis Cambridge Genomics Center’s efforts to acquire a set of siRNAs against 5,000 druggable genes from Dharmacon, quoting the center’s RNAi platform head Dorre Grueneberg.

Grueneberg said at the time that the center was planning on buying the siRNA set from Dharmacon for $285,000. Gruenberg, however, said this week that Qiagen is the seller of the set, not Dharmacon.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.